Non–Small Cell Lung Cancer, Version 6.2015
David S. Ettinger, Douglas E. Wood, Wallace Akerley et al. · Journal of the National Comprehensive Cancer Network · 2015
These NCCN Guidelines Insights focus on recent updates to the 2015 NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC). Appropriate targeted therapy is very effective in patients with advanced NSCLC who have specific genetic alterations. Therefore, it is important to test tumor tissue from patients with advanced NSCLC to determine whether they have genetic alterations that make them candidates for specific targeted therapies. These NCCN Guidelines Insights describe the different testing methods currently available for determining whether patients have genetic alterations in the 2 most commonly actionable genetic alterations, notably anaplastic lymphoma kinase (ALK) gene rearrangements and sensitizing epidermal growth factor receptor (EGFR) mutations.
Cited by 479 works. doi:10.6004/jnccn.2015.0071
Authors
- David S. Ettinger
- Douglas E. Wood
- Wallace Akerley
- Lyudmila A. Bazhenova
- Hossein Borghaei
- David Ross Camidge
- Richard T. Cheney
- Lucian R. Chirieac
- Thomas Anthony D’Amico
- Todd L. Demmy
- Thomas J. Dilling
- M.C. Dobelbower
- Ramaswamy Govindan
- Frederic W. Grannis
- Leora Horn
- Thierry Marie Jahan
- Ritsuko U Komaki
- Lee M. Krug
- Rudy P. Lackner
- Michael D. Lanuti
References
- The National Comprehensive Cancer Network
- Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- Cancer statistics, 2015
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
- First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK